中风险急性髓系白血病患者中可测量残余病导向治疗是减少异基因移植的有价值策略，不会对生存产生负面影响。
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
发表日期：2023 Apr 06
作者：
Jesse M Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A Breems, Thomas Fischer, Bjorn T Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J W M Janssen, Gunnar Juliusson, Johan Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter J M Valk, Bob Löwenberg, Gert J Ossenkoppele, Jacqueline Cloos
来源：
HAEMATOLOGICA
摘要：
不可用。
Not available.